Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company has received a Notice of Allowance for a patent around its work on chronic kidney disease.
Moreau tells Proactive the patent, which is titled “Compositions and Methods for Treating Non-Alcoholic Steatohepatitis”, is based around its kidney disease program with the drug NP-251 or Repirinast. This is the company’s first allowance notice received from the US patent office.
Proactive Canada
+1 604-688-8158
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.04 |
| Daily Change: | -0.003 -7.32 |
| Daily Volume: | 344 |
| Market Cap: | US$1.040M |
July 16, 2024 April 01, 2024 January 11, 2024 | |
Surf Air Mobility is a regional air mobility platform expanding the category of regional air travel to reinvent flying through the power of electrification. In an effort to substantially reduce the cost and environmental impact of...
CLICK TO LEARN MORE
Else Nutrition is changing the face of early childhood nutrition with clean, sustainable, plant-based products. The company has developed the world’s first whole plant-based infant formula that is targeting the $100+ billion global...
CLICK TO LEARN MORE